Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Consolidated Financial Statements for the First Quarter of the Fiscal Year Ending March 31, 2026 [Japanese GAAP]
VITAL KSK, Apr-Jun (1Q) Ordinary Profit Decreases by 33%
Notice Regarding Recording of Gain on Sale of Investment Securities (Extraordinary Income)
[Summary]Notice Regarding Completion of Payment for Disposal of Treasury Stockas Restricted Stock and Partial Forfeiture
[Updated]Notice Regarding Disposition of Treasury Stock for Performance-Linked Restricted Stock Compensation
[Updated]Notice of Change of Directors and Other Personnel in the Group
[Summary]Notice of Changes in Directors and Personnel of our Group
[Summary]Notice Regarding Disposition of Treasury Stock for Performance-Linked Restricted Stock Compensation
[Updated]Partial Revision of the Performance-Linked Restricted Stock Compensation Plan
[Updated]Notice of Organizational Changes, Change of Representative Director, Directors and Other Personnel
[Updated]Notice of Partial Amendments to the Articles of Incorporation
VITAL KSK, 14% Decrease in Ordinary Profit for The Current Fiscal Year, Dividend Raised by 23 yen
[Summary]Notice Regarding Disposition of Treasury Stock for Performance-Linked Restricted Stock Compensation
Notice of Dividend of Surplus
[Summary]Notice Regarding Partial Amendment to Performance-Linked Restricted Stock Compensation Plan
[Summary]Notice of Partial Amendments to the Articles of Incorporation
[Summary]Notice of organizational changes, changes in representative directors, changes in directors, and changes in personnel assignments
Consolidated Financial Statements for the Fiscal Year Ended March 31, 2025 [Japanese GAAP]
[Updated]Notice Regarding the Medium-Term Management Plan 2027 - Move on to the Next Stage -
Notice of Conclusion of Exclusive License Agreement of Shield Therapeutics Plc’s Iron Deficiency Treatment by Consolidated Subsidiary